Technology Holding, LLC SBIR Phase I Award, February 2021

Antibiotic resistant infections are a principal concern for the Department of Defense and society at large due to the current lack of available treatments. Monoclonal antibodies represent a promising drug class that could be applied to antibiotic resistant infections to harness a patients own immune system to effectively combat the invading threat. In this program we present an optimized workflow to yield high affinity monoclonal antibody candidates against surface antigens from common infectious disease which is increasingly antibiotic resistant.